GoldenGolden
Advanced Search
Adverum Biotechnologies

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

Contents
Funding Venture round ISeries B Venture round II
Timeline
Funding rounds
Products
Acquisitions
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

Funding
Venture round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.

Series B

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

Venture round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

Timeline

May 7, 2016
Merger of Avalanche Biotechnologies and Annapurna Therapeutics

The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

September 19, 2014
Venture funding round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

September 2014
Adverum Biotechnologies raises a $10,000,000 venture round.
April 22, 2014
Series B funding round

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

April 2014
Adverum Biotechnologies raises a $55,000,000 series B round from Adage Capital Management, Deerfield Management Company, Redmile Group, Rock Springs Capital, Sabby Capital and Venrock.
November 2, 2013
Venture funding round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investor

November 2013
Adverum Biotechnologies raises a $5,700,000 venture round.
July 25, 2006
Adverum Biotechnologies was founded by Mark S. Blumenkranz and Mitchell H. Finer.

Funding rounds

Powered by Golden Research Engine

People

Name
Role
LinkedIn

Mark S. Blumenkranz

Co-Founder

Carla Fiankan

Vice President, Regulatory Affairs

Claire Gelfman

Executive Director, Pharmaceutical Development

Jennifer Cheng

Vice President and General Council

Leone Patterson

CEO, Director, and CFO

Mehdi Gasmi

President and CSO

Michael Steel

Vice President, Quality

Mike Fitzgerald

Vice President , Human Resources

Mitchell H. Finer

Co-Founder

Pratik Jaluria

Executive Director, Process Development and Manufacturing

Steven D. Schwartz

Co-Founder

Thomas W. Chalberg

Co-Founder

Further reading

Title
Author
Link
Type
Date

Avalanche Biotechnologies Agrees to Buy Annapurna Therapeutics

Genenews

https://www.genengnews.com/topics/drug-discovery/avalanche-biotechnologies-agrees-to-buy-annapurna-therapeutics/

Web

Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today

Maxx Chatsko

https://www.fool.com/investing/2018/11/02/heres-why-adverum-biotechnologies-dropped-as-much.aspx

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Half of Adverum pipeline 'snaps out of existence' as adverse events force pivot to more common eye disease
Nick Paul
July 23, 2021
FierceBiotech
And just like that, half of Adverum Biotechnologies' pipeline is gone. The biotech announced after market Thursday that it would abandon a key eye disease indication and shift focus to another, but analysts aren't sure how the company will overcome the adverse events that sent them in the new, slimmed-down direction.
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
BioSpace
July 1, 2021
BioSpace
Adverum Biotechnologies, Inc. today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective immediately.
Adverum Announces Changes to Management Team
BioSpace
June 24, 2021
BioSpace
Adverum Biotechnologies, Inc. today announced that Leone Patterson, president and chief financial officer, has resigned to pursue another opportunity.
Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight
DelveInsight Business Research, LLP
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Diabetic Retinopathy Market Insights report offers detailed information on current treatment practices, emerging drugs, Diabetic...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Pomerantz LLP
May 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such...
Adverum shares halved after trial patient goes blind in one eye after experimental gene therapy
Ben Adams
April 29, 2021
FierceBiotech
Adverum saw its shares down more than 51% after-hours Wednesday night after a patient it was testing a gene therapy on for a common eye condition went blind in the treated eye.
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
BioSpace
April 22, 2021
BioSpace
Urges Stockholders to Vote the WHITE Proxy Card "FOR" ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc.
The Sonic Fund II, L.P.
April 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc....
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
BioSpace
November 14, 2020
BioSpace
Company to host webcast with Key Opinion Leaders to discuss new OPTIC data today, Saturday, November 14, 2020 at 7:30 am PT / 10:30 am ET

References

adverum.com
Is a
Company

Company attributes

Industry
Location
Company status
Active
B2X
‌
B2B
CEO
Leone Patterson
Founder
Crunchbase
crunchbase.com/organiz...nologies
Legal name
Adverum Biotechnologies, Inc.
Legal classification
Corporation
Date incorporated
July 25, 2006
Number of Employees (ranges)
100 – 249
Full address
800 SAGINAW DRIVE, REDWOOD CITY, CA, 94063
CIK number
1,501,756
Investors
Rock Springs Capital
Founded date
January 1, 2006
Total funding amount (USD)
70,700,000
Latest funding round date
September 2014
Competitors
Akouos
Latest funding type
Series B round

Other attributes

Country
United States

Categories

Related Topics

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
OverviewPricingEnterprise
Legal
Terms & ConditionsCommercial Terms & ConditionsPrivacy Policy
Help
Help centerAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.